Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS OCTOBER ISSUE PUBLISHED
  • OCTOBER 2020 Issue has been successfully launched on 1 October 2020.

Abstract

FEACAL MICROBIOTA TRANSPLANTS IN CLOSTRIDIUM DIFFICILE INFECTION, INFLAMMATORY BOWEL DISEASE, OBESITY, METABOLIC SYNDROME

*K. Rishitha, L. Divya Bhargavi, P. Deepthi, Dr. G. Ramesh, Satheesh S. Gottipati and Dr. P. Srinivasa Babu

ABSTRACT

Fecal microbiota transplantation (FMT) has been shown to be more effective in treating relapsing or refractory Clostridium difficile infection (CDI) and, potentially, inflammatory bowel disease (IBD). In clinical setting, the FMT was noted to significantly lower the risk of recurrent CDI, likely by increasing microbial diversity and altering the metabolic environment in the intestinal tract of recipients. The efficacy of FMT in the treatment of IBD appears to be influenced by a number of factors, including donor microbial profiles, inflammatory burden, and the microbial diversity of the recipient. The administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s gut microbial composition and confer a health benefit is fecal microbiota transplantation (FMT). It may also carry therapeutic potential for other conditions such as inflammatory bowel disease, obesity, metabolic syndrome, and functional gastrointestinal disorders.

Keywords: Fecal bacteriotherapy, Clostridium difficile infection, Inflammatory bowel disease, gutmicrobiome, Probiotics.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More